Personalized medicine, or individually tailored patient treatment, is an emerging clinical management paradigm. In nuclear medicine, this entails exploiting diagnostic techniques, such as non-invasive imaging by means of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), to modify radiotherapeutic treatment regimes. If the same drug is labeled with a diagnostic and a therapeutic radionuclide for sequential imaging and treatment, the approach is considered “theranostic.” Theranostic isotope pairs enable diagnostic imaging that is directly, accurately and reliably predictive of therapy and imaging can be carried out for prolonged periods of time. However, in order to utilize metallic theranostic isotope pairs, customized chelation approaches are required that enable targeted delivery of isotope payload to the site of interest.
44Scandium and 64copper have recently emerged as an attractive, short-lived, PET isotopes with a matched radiotherapeutic isotope for radio therapy (47Sc, 67Cu, 177Lu). In this invention, novel, modular chemical entities with high affinity to copper, scandium and lutetium radioisotopes and a freely functionalizable moiety have been synthesized. These constructs are suitable to kit-type formulations for single-step radiochemical synthesis of diagnostic and therapeutic entities radiolabeled with scandium, copper and lutetium isotopes, and are readily suitable for applications using other any desirable targeting vectors of peptidic/small molecule, protein or antibody nature.
This technology allows for rapid and inert radiolabeling with an array of radioactive isotopes suitable for imaging and therapy approaches. This renders the technology superior to currently commercially available 18F-, 68G-, and 177Lu-based tracers.
Cancer diagnostics and therapeutics.
Eszter Boros, Assistant Professor, Chemistry
Brett Vaughn, , Chemistry
Development partner - Commercial partner - Licensing
Available for licensing
Valery Matthys, Licensing Associate, Intellectual Property Partners, email@example.com,
PCT/US2019/038318; PCT 2021-0276971-A!
Preclinical, animal data available.